BIIB Q3 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B+0.9% YoY

Gross Profit

$1.9B73.9% margin

Operating Income

$321M12.7% margin

Net Income

-$68M-2.7% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+3.0%

Cash Flow

Operating Cash Flow

$592M

Free Cash Flow

$505M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$28.2B

Total Liabilities

$13.7B

Stockholders' Equity

$14.5B

Cash & Equivalents

$2.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.5B	+0.9%
Gross Profit	$1.9B	$2.0B	-8.3%
Operating Income	$321M	$870M	-63.1%
Net Income	-$68M	$1.1B	-106.0%

Revenue Segments

MS Product Revenues

$1.2B42%

TYSABRI product

$456M17%

SPINRAZA

$448M16%

Fumarate

$405M15%

Interferon

$278M10%

Geographic Segments

Non-US

$1.0B56%

UNITED STATES

$791M44%